Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau183lec

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 28	CA/CAplus patent coverage enhanced
NEWS 3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5	JUL 28	STN Viewer performance improved
NEWS 6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 9	AUG 15	CAplus currency for Korean patents enhanced
NEWS 10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 12	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 14	SEP 29	IFICLS enhanced with new super search field
NEWS 15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS 19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS 20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS 21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:04:32 ON 18 NOV 2008

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 17:04:46 ON 18 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 17 Nov 2008 (20081117/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s 6-methylmercaptopurine (w) riboside
       4190652 6
           326 METHYLMERCAPTOPURINE
           285 6-METHYLMERCAPTOPURINE
                 (6(W)METHYLMERCAPTOPURINE)
          4426 RIBOSIDE
L1         111 6-METHYLMERCAPTOPURINE (W) RIBOSIDE

=> s l1 and N-phosphonacetyl-L-aspartic acid
       3243595 N
           371 PHOSPHONACETYL
       1711911 L
         76309 ASPARTIC
       4710213 ACID
             62 N-PHOSPHONACETYL-L-ASPARTIC ACID
                 (N(W)PHOSPHONACETYL(W)L(W)ASPARTIC(W)ACID)
L2            3 L1 AND N-PHOSPHONACETYL-L-ASPARTIC ACID
```

```
=> s l2 and alanosine
           201 ALANOSINE
L3           0 L2 AND ALANOSINE

=> s l2 and 3-bromopyruvate
       7433128 3
          1057 BROMOPYRUVATE
           150 3-BROMOPYRUVATE
                 (3(W)BROMOPYRUVATE)
L4           0 L2 AND 3-BROMOPYRUVATE

=> s l2 and adriamycin
         12068 ADRIAMYCIN
L5           2 L2 AND ADRIAMYCIN

=> d l2 ibib abs hitstr 1-2

L2   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         1996:125542  CAPLUS
DOCUMENT NUMBER:          124:219696
ORIGINAL REFERENCE NO.:   124:40305a,40308a
TITLE:                    Enhanced antitumor activity of an adriamycin +
                          5-fluorouracil combination when preceded by
                          biochemical modulation
AUTHOR(S):                Stolfi, Robert L.; Colofiore, Joseph R.; Nord, L. D.;
                          Martin, Daniel S.
CORPORATE SOURCE:         Catholic Medical Center, Woodhaven, NY, 11421, USA
SOURCE:                   Anti-Cancer Drugs (1996), 7(1), 100-4
                          CODEN: ANTDEV; ISSN: 0959-4973
PUBLISHER:                Rapid Science Publishers
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   A three-drug combination, PMA, consisting of (phosphonacetyl)-L-aspartic
     acid + 6-methylmercaptopurine riboside +
     5-aminonicotinamide, preceding either 5-fluorouracil (5-FU) or adriamycin
     (Adr), produced tumor-regressing activity in a murine advanced breast
     tumor model not attainable with either 5-FU or Adr as single agents, or
     with any lesser combination of these drugs administered at maximally
     tolerated doses.  Marked tumor-regressing activity was further increased
     significantly by using 5-FU and Adr together in conjunction with the
     modulatory biochem. conditioning (particularly ATP depletion) provided by
     pretreatment with PMA.

L2   ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         1994:95764  CAPLUS
DOCUMENT NUMBER:          120:95764
ORIGINAL REFERENCE NO.:   120:16835a,16838a
TITLE:                    Chemotherapeutic drug combinations
INVENTOR(S):              Martin, Daniel S.; Stolfi, Robert L.; Colofiore,
                          Joseph R.; Nord, L. D.
PATENT ASSIGNEE(S):       USA
SOURCE:                   PCT Int. Appl., 79 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
```

```
     WO 9323014           A1    19931125    WO 1993-US4775         19930520
         W:  AU, CA, JP
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     AU 9343834           A     19931213    AU 1993-43834          19930520
     AU 684709            B2    19980108
     EP 641193            A1    19950308    EP 1993-914010         19930520
         R:  AT, BE, CH, DE, FR, GB, IE, IT, LI, NL
     JP 08506317          T     19960709    JP 1993-503842         19930520
PRIORITY APPLN. INFO.:                       US 1992-885809      A  19920520
                                             WO 1993-US4775      A  19930520
```

AB Drug combinations for the treatment of neoplastic diseases comprise (1) cellular energy depletion compns. containing an inhibitor of purine nucleotide biosynthesis, a nicotinamide antagonist, and optionally an inhibitor of pyrimidine nucleotide biosynthesis and (2) apoptosis-inducing agents. For example, antineoplastic effects of combinations of N-(phosphonacetyl)-L-aspartic acid, 6-methylmercaptopurine riboside, 6-aminonicotinamide, and 5-fluorouracil in breast tumor-bearing mice were demonstrated.

```
=> d his

     (FILE 'HOME' ENTERED AT 17:04:32 ON 18 NOV 2008)

     FILE 'CAPLUS' ENTERED AT 17:04:46 ON 18 NOV 2008
L1          111 S 6-METHYLMERCAPTOPURINE (W) RIBOSIDE
L2            3 S L1 AND N-PHOSPHONACETYL-L-ASPARTIC ACID
L3            0 S L2 AND ALANOSINE
L4            0 S L2 AND 3-BROMOPYRUVATE
L5            2 S L2 AND ADRIAMYCIN

=> d l2 ibib abs hitstr 3

L2   ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        1992:542977  CAPLUS
DOCUMENT NUMBER:         117:142977
ORIGINAL REFERENCE NO.:  117:24565a,24568a
TITLE:                   Biochemical modulation of tumor cell energy:
                         regression of advanced spontaneous murine breast
                         tumors with 5-fluorouracil-containing drug combination
AUTHOR(S):               Stolfi, Robert L.; Colofiore, Joseph R.; Nord, L. D.;
                         Koutcher, Jason A.; Martin, Daniel S.
CORPORATE SOURCE:        Cancer Res. Dep., Cathol. Med. Cent., Woodhaven, NY,
                         11421, USA
SOURCE:                  Cancer Research (1992), 52(15), 4074-81
                         CODEN: CNREA8; ISSN: 0008-5472
DOCUMENT TYPE:           Journal
LANGUAGE:                English
```

AB This report describes a highly active chemotherapeutic drug combination, consisting of N-(phosphonacetyl)-L-aspartate plus 6-methylmercaptopurine riboside plus 6-aminonicotinamide plus 5-fluorouracil, in CD8F1 mice bearing spontaneous, autochthonous, breast tumors or first-passage advanced transplants of these spontaneous tumors. The combination and sequence of administration of these drugs were selected on the basis of known potentiating biochem. interactions. High performance liquid chromatog. and NMR spectroscopy measurements of biochem. changes resulting from treatment with N-(phosphonacetyl)-L-aspartate plus 6-methylmercaptopurine riboside plus 6-aminonicotinamide indicated a severe depletion of cellular energy levels in the treated

tumors. 6-Aminonicotinamide produced a severe block of the pentose shunt, and 5-fluorouracil severely inhibited both thymidylate synthase and thymidine kinase in the treated tumors. This quadrupole drug combination, administered on a 10-11-day schedule, produced an impressive partial tumor regression rate of 67% of large, spontaneous, autochthonous, murine breast tumors and a tumor regression rate of 74% of first-passage transplants of the spontaneous breast tumors.

=> d his

(FILE 'HOME' ENTERED AT 17:04:32 ON 18 NOV 2008)

FILE 'CAPLUS' ENTERED AT 17:04:46 ON 18 NOV 2008
L1 111 S 6-METHYLMERCAPTOPURINE (W) RIBOSIDE
L2 3 S L1 AND N-PHOSPHONACETYL-L-ASPARTIC ACID
L3 0 S L2 AND ALANOSINE
L4 0 S L2 AND 3-BROMOPYRUVATE
L5 2 S L2 AND ADRIAMYCIN

=> d l5 ibib abs hitstr 1-2

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:125542 CAPLUS
DOCUMENT NUMBER: 124:219696
ORIGINAL REFERENCE NO.: 124:40305a,40308a
TITLE: Enhanced antitumor activity of an adriamycin + 5-fluorouracil combination when preceded by biochemical modulation
AUTHOR(S): Stolfi, Robert L.; Colofiore, Joseph R.; Nord, L. D.; Martin, Daniel S.
CORPORATE SOURCE: Catholic Medical Center, Woodhaven, NY, 11421, USA
SOURCE: Anti-Cancer Drugs (1996), 7(1), 100-4
CODEN: ANTDEV; ISSN: 0959-4973
PUBLISHER: Rapid Science Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A three-drug combination, PMA, consisting of (phosphonacetyl)-L-aspartic acid + 6-methylmercaptopurine riboside + 5-aminonicotinamide, preceding either 5-fluorouracil (5-FU) or adriamycin (Adr), produced tumor-regressing activity in a murine advanced breast tumor model not attainable with either 5-FU or Adr as single agents, or with any lesser combination of these drugs administered at maximally tolerated doses. Marked tumor-regressing activity was further increased significantly by using 5-FU and Adr together in conjunction with the modulatory biochem. conditioning (particularly ATP depletion) provided by pretreatment with PMA.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:95764 CAPLUS
DOCUMENT NUMBER: 120:95764
ORIGINAL REFERENCE NO.: 120:16835a,16838a
TITLE: Chemotherapeutic drug combinations
INVENTOR(S): Martin, Daniel S.; Stolfi, Robert L.; Colofiore, Joseph R.; Nord, L. D.
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9323014	A1	19931125	WO 1993-US4775	19930520
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9343834	A	19931213	AU 1993-43834	19930520
AU 684709	B2	19980108		
EP 641193	A1	19950308	EP 1993-914010	19930520
R: AT, BE, CH, DE, FR, GB, IE, IT, LI, NL				
JP 08506317	T	19960709	JP 1993-503842	19930520
PRIORITY APPLN. INFO.:			US 1992-885809 A	19920520
			WO 1993-US4775 A	19930520

AB Drug combinations for the treatment of neoplastic diseases comprise (1) cellular energy depletion compns. containing an inhibitor of purine nucleotide biosynthesis, a nicotinamide antagonist, and optionally an inhibitor of pyrimidine nucleotide biosynthesis and (2) apoptosis-inducing agents. For example, antineoplastic effects of combinations of N-(phosphonacetyl)-L-aspartic acid, 6-methylmercaptopurine riboside, 6-aminonicotinamide, and 5-fluorouracil in breast tumor-bearing mice were demonstrated.

=> d his

(FILE 'HOME' ENTERED AT 17:04:32 ON 18 NOV 2008)

FILE 'CAPLUS' ENTERED AT 17:04:46 ON 18 NOV 2008
L1 111 S 6-METHYLMERCAPTOPURINE (W) RIBOSIDE
L2 3 S L1 AND N-PHOSPHONACETYL-L-ASPARTIC ACID
L3 0 S L2 AND ALANOSINE
L4 0 S L2 AND 3-BROMOPYRUVATE
L5 2 S L2 AND ADRIAMYCIN